Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

82.48CHF
17 Aug 2018
Change (% chg)

CHF0.76 (+0.93%)
Prev Close
CHF81.72
Open
CHF82.20
Day's High
CHF82.58
Day's Low
CHF81.98
Volume
4,607,912
Avg. Vol
4,651,933
52-wk High
CHF88.30
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.12
Market Cap(Mil.): CHF210,185.50
Shares Outstanding(Mil.): 2,550.62
Dividend: 2.80
Yield (%): 3.39

Financials

  NOVN.S Industry Sector
P/E (TTM): 14.10 28.29 30.45
EPS (TTM): 5.84 -- --
ROI: 12.45 12.92 12.63
ROE: 18.79 14.94 14.82

Bank DNB switches US, Europe mutual funds to index tracking

OSLO, Aug 14 Norwegian bank DNB will switch its mutual funds for U.S. and European stocks to index tracking from active management on Aug. 16, it said on Tuesday.

Aug 14 2018

Novartis recruits new compliance head from Siemens after ethics stumbles

ZURICH Novartis has recruited a new chief ethics officer from Siemens after costly bribery scandals and a disputed $1.2 million contract with President Donald Trump's former lawyer that the Swiss drugmaker now calls a mistake.

Aug 14 2018

Novartis recruits new compliance head from Siemens after ethics stumbles

* Novartis hires Siemens lawyer to lead anti-corruption efforts

Aug 14 2018

BRIEF-Novartis appoints Klaus Moosmayer as Chief Ethics Risk and Compliance Officer

* SAYS NOVARTIS APPOINTS DR. KLAUS MOOSMAYER AS CHIEF ETHICS RISK AND COMPLIANCE OFFICER Further company coverage: (Reporting By Zurich newsroom)

Aug 14 2018

Fed. Circuit upholds decision canceling claims in Durezol eyedrops patent

A federal appeals court on Wednesday upheld a ruling that invalidated a patent covering Novartis AG's Durezol, opening the door for Akorn Inc to launch a generic version of the eye medication.

Aug 08 2018

BRIEF-Novartis Announces U.S. Renewables Agreement To Reduce Greenhouse Gas Emissions

* NOVARTIS ANNOUNCES US RENEWABLES AGREEMENT TO REDUCE GREENHOUSE GAS EMISSIONS

Aug 02 2018

More drugmakers build Brexit stockpiles as EU agency faces exodus

PARIS/ZURICH/LONDON Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal. | Video

Aug 01 2018

More drugmakers build Brexit stockpiles as EU agency faces exodus

PARIS/ZURICH/LONDON Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal.

Aug 01 2018

UPDATE 3-More drugmakers build Brexit stockpiles as EU agency faces exodus

* Sanofi and Novartis action follows similar move by AstraZeneca

Aug 01 2018

BRIEF-MerLion Regains North American Rights to XTORO

* MERLION PHARMACEUTICALS- NOVARTIS HAS MADE A PORTFOLIO DECISION AND TERMINATED LICENSE BETWEEN ALCON AND MERLION EXECUTED IN 2010

Jul 31 2018

Earnings vs. Estimates